checkAd
    60 Degrees Pharmaceuticals Aktie
    0,2920
     
    USD
    +0,76 %
    +0,0022 USD
    Letzter Kurs 02:00:00 Nasdaq
    0,2910
     
    USD
    1.000 STK
    Geldkurs 31.05.24
    0,2960
     
    USD
    4.000 STK
    Briefkurs 31.05.24
    ISIN: US83006G1040 · WKN: A3END4 · SYM: SXTP · USA

    Neueste Nachrichten

    Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
    30.05.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
    20.05.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
    15.05.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
    08.05.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
    02.05.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
    03.04.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
    14.03.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
    20.02.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
    08.02.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
    31.01.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
    30.01.24 · globenewswire · 60 Degrees Pharmaceuticals
    60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
    22.01.24 · globenewswire · 60 Degrees Pharmaceuticals